NCT05262491View on ClinicalTrials.gov

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Gastrointestinal Tumor
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion

Trial Locations (6)

100037

RECRUITING

Beijing Cancer Hospital, Beijing

Unknown

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

West China Hospital, Sichuan University, Chengdu

RECRUITING

Tianjin Medical University General Hospital, Tianjin

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05262491 - A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor | Biotech Hunter | Biotech Hunter